Efficacy of sibutramine in different types of eating behavior in obese patients

Abstract

Introduction. One of the key factors contributing to the development and progression of obesity is impairment eating behavior (EB). Therefore, drug therapy for obesity should not only reduce hunger, contributing to weight loss, but also reducing the severity of EB disorders.Aim. Assess the representation of different types of EB in obese patients, the effect of sibutramine therapy on dynamics EB by The Dutch Eating Behavior Questionnaire (DEBQ) and for hunger/satiety on a visual analog scale (VAS). Quality life of patients, adherence to treatment of obese patients and their weight dynamics in different types of EB during therapy with sibutramine was also assessed.Materials and methods. The study included 36 obese patients (30 women and 6 men), mean age 38.7 ± 10.8 years, mean body weight 102.8 ± 16.4 kg, body mass index (BMI) 36.8 ± 4.6 kg/m2, receiving therapy with sibutramine at a dose of 10 mg per day once in the morning before meals in combination with hypocaloric nutrition.Results and discussion. The study showed the prevalence of the emotiogenic type of eating disorders in patients. However, it was pointed out that sibutramine therapy combined with hypocaloric nutrition proved its efficacy in any type of eating disorders. Positive dynamics anxiety/depression in subclinical conditions during treatment with sibutramine was also revealed.Conclusion. Sibutramine treatment may be recommended for the development of a new EB model in obese patients because it is effective in reducing weight in any type of EB disorder.

Liraglutide and sibutramine: similarities and differences in pharmacotherapy of obesity

“…Матвеевым и А.Ю. Бабенко (2022), также подтверждена высокая эффективность терапии сибутрамином (Редуксином) в течение 6 мес при любом типе ПП [56].…”

Management of obesity: pharmacological approach

“…Также у данной группы больных отмечался положительный эффект в отношении субклинических состояний в виде уменьшения чувства тревожности на 31,3% и депрессии на 28,6%, что может быть обусловлено позитивным влиянием снижения массы тела на их психоэмоциональное состояние. Стоит отметить, что у группы больных с экстернальным и ограничительным типами РПП прием сибутрамина не оказал выраженного положительного либо отрицательного влияния на эмоциональное состояние [19].…”